Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
暂无分享,去创建一个
E. Goetghebeur | Y. Lievens | S. Rottey | L. Brochez | N. Sundahl | D. D. De Maeseneer | P. Ost | P. Dirix | D. Reynders | F. Duprez | V. Kruse | R. Van den Begin | D. Van Gestel | V. Surmont | V. Renard | M. Spaas | Willeke Danckaert | W. Danckaert
[1] F. Lohr,et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.
[2] Yibo Gao,et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. , 2021, The Lancet. Oncology.
[3] E. Goetghebeur,et al. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial , 2021, BMC cancer.
[4] S. Loi,et al. Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial. , 2021 .
[5] R. Weichselbaum,et al. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial , 2020, Clinical Cancer Research.
[6] N. Lee,et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Louie,et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial , 2020, BMC Cancer.
[8] W. Woodward,et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] B. Yaremko,et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.
[10] R. Weichselbaum,et al. Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” , 2020, Clinical Cancer Research.
[11] L. Collette,et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.
[12] C. Dooms,et al. Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] B. Kavanagh,et al. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy. , 2019, International journal of radiation oncology, biology, physics.
[14] J. Aerts,et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[15] B. Neyns,et al. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. , 2019, International journal of radiation oncology, biology, physics.
[16] Clemens Grassberger,et al. Assessing the interactions between radiotherapy and antitumour immunity , 2019, Nature Reviews Clinical Oncology.
[17] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[18] E. Goetghebeur,et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.
[19] Joe Y. Chang,et al. Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.
[20] Manish R. Sharma,et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Formenti,et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.
[22] C. N. Coleman,et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.